Table 1

Characteristics of included studies (more details in online supplementary table 1)

Source, year refSample sizePatient treatment historyCompared interventionsContrasts usedBackground treatmentDisease duration (years)HAQSwollen joint count
PlaceboActive
Placebo control
Smolen, 20082623MTX-IR3. Tcz 8 mg/kg IV/4 weeks vs1 vs 32 vs 3MTX7.61.5720
2. Tcz 4 mg/kg IV/4 weeks vs
1. Placebo
Genovese, 200841216DMARD-IR2. Tcz 8 mg/kg IV/4 weeks vs1 vs 2DMARD9.81.5019
1. Placebo
Kremer, 200861196MTX-IR3. Tcz 8 mg/kg IV/4 weeks vs1 vs 32 vs 3MTX9.21.5017
2. Tcz 4 mg/kg IV/4 weeks vs
1. Placebo
Weinblatt, 20038271MTX-IR4. Ada 80 mg SC/2 weeks vs1 vs 42 vs 3MTX12.31.5717
3. Ada 40 mg SC/2 weeks vs
2. Ada 20 mg SC/2 weeks vs
1. Placebo
Furst, 20039636DMARD-IR2. Ada 40 mg/2 weeks SC vs1 vs 2Standard antirheumatic treatment10.41.421
1. Placebo
Van de Putte, 200410544DMARD-IR5. Ada 40 mg/2 weeks SC vs1 vs 52 vs 3Usual concomitant treatment10.91.8620
<</p>4. Ada 40 mg/week SC vs4 vs 5
3. Ada 20 mg/2 weeks SC vs
2. Ada 20 mg/week SC vs
1. Placebo
Keystone, 200411619MTX-IR3. Ada 40 mg/2 weeks SC vs1 vs 32 vs 3MTX11.01.4619
2. Ada 20 mg/2 weeks SC vs
1. Placebo
Weinblatt, 19991289MTX-IR2. Etan 25 mg/2 weeks SC vs1 vs 2MTX13.01.518
1. Placebo
Combe, 200613254SSZ-IR3. Etan 25 mg SC/2 weeks + SSZ 2–3 g/day vs1 vs 32 vs 3None6.41.6319
2. Etan 25 mg SC/2 weeks vs
1. SSZ 2–3 g/day
Moreland, 199914234DMARD-IR3. Etan 25 mg/2 weeks SC vs1 vs 32 vs 3None12.01.6725
2. Etan 10 mg/2 weeks SC vs
1. Placebo
Schiff, 200815431MTX-IR3. Ifx 3 mg/kg/8 weeks IV vs*2 vs 3MTX7.91.7720
2. Aba 10 mg/kg/month IV vs
1. Placebo
Kremer, 200316339MTX-IR3. Aba 10 mg/kg/month IV vs1 vs 32 vs 3MTX9.41.0021
2. Aba 2 mg/kg/month IV vs
1. Placebo
Kremer, 200617652MTX-IR2. Aba 10 mg/kg/month IV vsMTX8.7NRNR
1. Placebo
Emery, 200618465DMARD including biological agents-IR3. Rtx 2× 1.0 g IV in 2 weeks vs1 vs 32 vs 3MTX10.41.7322
<</p>2. Rtx 2× 0.5 g IV in 2 weeks vs
1. Placebo
Cohen, 200619499aTNF-IR2. Rtx vs1 vs 2MTX11.91.923
1. Placebo
Emery, 20083489aTNF-IR3. Tcz 8 mg/kg IV/4 weeks vs1 vs 32 vs 3MTX11.61.719
2. Tcz 4 mg/kg IV/4 weeks vs
1. Placebo
Active control
Jones, 20095572No MTX in prev 6 months2. Tcz 8 mg/kg IV/4 weeks vs1 vs 2None9.81.619
<</p>1. MTX
Bathon 200020622No MTX in prev 6 months3. Etan 25 mg/2 weeks SC vs1 vs 3None1.0NRNR
<</p>2. Etan 10 mg//2 weeks SC vs2 vs 3
1. MTX
Johnsen, 20062177Failed ⩾1 DMARD2. Etan 50 mg/2 weeks SC vs1 vs 2None13.81.722
1. Etan 25 mg/2 weeks SC
Klareskog, 20047686DMARD-IR3. Etan 25 mg/2 weeks SC + MTX vs1 vs 3None6.61.723
2. Etan 25 mg/2 weeks SC vs2 vs 3
1. MTX
  • *The report was incomplete for the placebo results.

  • Aba, abatacept; Ada, adalimumab; aTNF, anti-tumour necrosis factor; DMARD, disease-modifying antirheumatic drug; Etan, etanercept; HAQ, Health Assessment Questionnaire; Ifx, infliximab; IR, inadequate response; IV, intravenously; MTX, methotrexate; NR, not reported; Rtx, rituximab; SC, subcutaneously; SSZ, sulfasalazine; Tcz, tocilizumab.